Antibody drug maker KaloBios seeks $60M IPO

David Pritchard.

KaloBios Pharmaceuticals Inc. seeks to raise $60 million in an initial public offering, the company said Friday. It is the second IPO by a Bay Area life sciences company in the past week. Heart disease test maker Singulex Inc. filed Sept. 28 for an $86 million IPO. The IPO from South San Francisco's KaloBios, which makes disease-fighting antibodies, comes as no surprise. As the company brought on Jeff Cooper this summer as its first chief financial officer, President and CEO David Pritchard told the San Francisco Business Times that he expected to file IPO paperwork sometime over the next 12 months.

KaloBios pulls in $10M debt financing with option to borrow $5M more

KaloBios Pharmaceuticals Inc. raised $10 million, with an option to borrow an additional $5 million, in a debt financing with MidCap Financial SBIC LP. South San Francisco-based KaloBios will use the money to advance clinical development of its monoclonal antibody drugs, including Phase II trials of its severe asthma drug and a treatment for cystic fibrosis patients, and for general corporate purposes.

KaloBios aims its antibodies at an IPO, trio of trials

More than disease-fighting antibodies are on the agenda of KaloBios Pharmaceuticals Inc. Its sights are set on an IPO.

To that end, KaloBios said this week that it hired former BioMarin Pharmaceutical Inc. executive Jeff Cooper as its first chief financial officer. Cooper is charged with overseeing all that leads up to the South San Francisco company's initial public offering over the next 12 months, said President and CEO David Pritchard.

KaloBios Pharmaceuticals starts test of potential leukemia drug

KaloBios Pharmaceuticals Inc. started an early stage test of a treatment aimed at leukemia.
The South San Francisco business treated the first patient in a Phase I trial of KB004, a monoclonal antibody the company has developed. The drug targets the protein EphA3, which is significant in several types of cancer.